Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial.

Huhn M, Leucht C, Rothe P, Dold M, Heres S, Bornschein S, Schneider-Axmann T, Hasan A, Leucht S.

Eur Arch Psychiatry Clin Neurosci. 2020 Feb 15. doi: 10.1007/s00406-020-01109-y. [Epub ahead of print]

PMID:
32062728
2.

The Efficacy of Light Therapy in the Treatment of Seasonal Affective Disorder: A Meta-Analysis of Randomized Controlled Trials.

Pjrek E, Friedrich ME, Cambioli L, Dold M, Jäger F, Komorowski A, Lanzenberger R, Kasper S, Winkler D.

Psychother Psychosom. 2020;89(1):17-24. doi: 10.1159/000502891. Epub 2019 Oct 1.

PMID:
31574513
3.

Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice.

Bartova L, Dold M, Kautzky A, Fabbri C, Spies M, Serretti A, Souery D, Mendlewicz J, Zohar J, Montgomery S, Schosser A, Kasper S.

World J Biol Psychiatry. 2019 Jul;20(6):427-448. doi: 10.1080/15622975.2019.1635270. Epub 2019 Jul 25.

PMID:
31340696
4.

Major Depression and Comorbid Diabetes - Findings from the European Group for the Study of Resistant Depression.

Fugger G, Dold M, Bartova L, Kautzky A, Souery D, Mendlewicz J, Serretti A, Zohar J, Montgomery S, Frey R, Kasper S.

Prog Neuropsychopharmacol Biol Psychiatry. 2019 Aug 30;94:109638. doi: 10.1016/j.pnpbp.2019.109638. Epub 2019 May 2.

PMID:
31054944
5.

Comorbid hypertension in patients with major depressive disorder - Results from a European multicenter study.

Fugger G, Dold M, Bartova L, Kautzky A, Souery D, Mendlewicz J, Serretti A, Zohar J, Montgomery S, Frey R, Kasper S.

Eur Neuropsychopharmacol. 2019 Jun;29(6):777-785. doi: 10.1016/j.euroneuro.2019.03.005. Epub 2019 Apr 18.

PMID:
31006562
6.

Psychotic Features in Patients With Major Depressive Disorder: A Report From the European Group for the Study of Resistant Depression.

Dold M, Bartova L, Kautzky A, Porcelli S, Montgomery S, Zohar J, Mendlewicz J, Souery D, Serretti A, Kasper S.

J Clin Psychiatry. 2019 Jan 15;80(1). pii: 17m12090. doi: 10.4088/JCP.17m12090.

PMID:
30677267
7.

Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples.

Fabbri C, Kasper S, Kautzky A, Bartova L, Dold M, Zohar J, Souery D, Montgomery S, Albani D, Raimondi I, Dikeos D, Rujescu D, Uher R, Lewis CM, Mendlewicz J, Serretti A.

Br J Psychiatry. 2019 Jan;214(1):36-41. doi: 10.1192/bjp.2018.256. Epub 2018 Nov 23.

PMID:
30468137
8.

Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study.

Dold M, Bartova L, Kautzky A, Serretti A, Porcelli S, Souery D, Mendlewicz J, Montgomery S, Zohar J, Kasper S.

Eur Neuropsychopharmacol. 2018 Dec;28(12):1305-1313. doi: 10.1016/j.euroneuro.2018.10.003. Epub 2018 Nov 13.

PMID:
30446357
9.

Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study.

Kautzky A, Dold M, Bartova L, Spies M, Kranz GS, Souery D, Montgomery S, Mendlewicz J, Zohar J, Fabbri C, Serretti A, Lanzenberger R, Dikeos D, Rujescu D, Kasper S.

Acta Psychiatr Scand. 2019 Jan;139(1):78-88. doi: 10.1111/acps.12959. Epub 2018 Oct 5.

10.

Rapid antidepressant effect of S-ketamine in schizophrenia.

Bartova L, Papageorgiou K, Milenkovic I, Dold M, Weidenauer A, Willeit M, Winkler D, Kasper S.

Eur Neuropsychopharmacol. 2018 Aug;28(8):980-982. doi: 10.1016/j.euroneuro.2018.05.007. Epub 2018 Jul 2.

PMID:
30041987
11.

International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets.

Caraci F, Calabrese F, Molteni R, Bartova L, Dold M, Leggio GM, Fabbri C, Mendlewicz J, Racagni G, Kasper S, Riva MA, Drago F.

Pharmacol Rev. 2018 Jul;70(3):475-504. doi: 10.1124/pr.117.014977. Review.

PMID:
29884653
12.

Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD).

Dold M, Bartova L, Fugger G, Kautzky A, Souery D, Mendlewicz J, Papadimitriou GN, Dikeos D, Ferentinos P, Porcelli S, Serretti A, Zohar J, Montgomery S, Kasper S.

Int J Neuropsychopharmacol. 2018 Jun 1;21(6):539-549. doi: 10.1093/ijnp/pyy009.

13.

Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD).

Fugger G, Dold M, Bartova L, Kautzky A, Souery D, Mendlewicz J, Serretti A, Zohar J, Montgomery S, Frey R, Kasper S.

Eur Neuropsychopharmacol. 2018 Jun;28(6):752-760. doi: 10.1016/j.euroneuro.2018.03.011. Epub 2018 Apr 26.

PMID:
29705022
14.

Clinical correlates of augmentation/combination treatment strategies in major depressive disorder.

Dold M, Bartova L, Mendlewicz J, Souery D, Serretti A, Porcelli S, Zohar J, Montgomery S, Kasper S.

Acta Psychiatr Scand. 2018 May;137(5):401-412. doi: 10.1111/acps.12870. Epub 2018 Feb 28.

15.

Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression.

Olgiati P, Serretti A, Souery D, Dold M, Kasper S, Montgomery S, Zohar J, Mendlewicz J.

J Affect Disord. 2018 Feb;227:777-786. doi: 10.1016/j.jad.2017.11.004. Epub 2017 Nov 10.

PMID:
29254066
16.

Refining Prediction in Treatment-Resistant Depression: Results of Machine Learning Analyses in the TRD III Sample.

Kautzky A, Dold M, Bartova L, Spies M, Vanicek T, Souery D, Montgomery S, Mendlewicz J, Zohar J, Fabbri C, Serretti A, Lanzenberger R, Kasper S.

J Clin Psychiatry. 2018 Jan/Feb;79(1). pii: 16m11385. doi: 10.4088/JCP.16m11385.

PMID:
29228516
17.

Low comorbid obsessive-compulsive disorder in patients with major depressive disorder - Findings from a European multicenter study.

Dold M, Bartova L, Souery D, Mendlewicz J, Porcelli S, Serretti A, Zohar J, Montgomery S, Kasper S.

J Affect Disord. 2018 Feb;227:254-259. doi: 10.1016/j.jad.2017.10.033. Epub 2017 Oct 28.

PMID:
29107818
18.

Dose Escalation of Antidepressants in Unipolar Depression: A Meta-Analysis of Double-Blind, Randomized Controlled Trials.

Dold M, Bartova L, Rupprecht R, Kasper S.

Psychother Psychosom. 2017;86(5):283-291. doi: 10.1159/000477770. Epub 2017 Sep 14.

PMID:
28903107
19.

The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes - Results from a cross-sectional European multicenter study.

Dold M, Bartova L, Kautzky A, Souery D, Mendlewicz J, Serretti A, Porcelli S, Zohar J, Montgomery S, Kasper S.

Eur Neuropsychopharmacol. 2017 Jul;27(7):625-632. doi: 10.1016/j.euroneuro.2017.05.004. Epub 2017 May 31.

PMID:
28579072
20.

Robust Antidepressant Effect Following Alternating Intravenous Racemic Ketamine and Electroconvulsive Therapy in Treatment-Resistant Depression: A Case Report.

Bartova L, Weidenauer A, Dold M, Naderi-Heiden A, Kasper S, Willeit M, Praschak-Rieder N.

J ECT. 2017 Sep;33(3):e31-e32. doi: 10.1097/YCT.0000000000000421. No abstract available.

PMID:
28520578
21.

Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study.

Dold M, Bartova L, Souery D, Mendlewicz J, Serretti A, Porcelli S, Zohar J, Montgomery S, Kasper S.

J Psychiatr Res. 2017 Aug;91:1-13. doi: 10.1016/j.jpsychires.2017.02.020. Epub 2017 Feb 27.

PMID:
28284107
22.

Evidence-based pharmacotherapy of treatment-resistant unipolar depression.

Dold M, Kasper S.

Int J Psychiatry Clin Pract. 2017 Mar;21(1):13-23. doi: 10.1080/13651501.2016.1248852. Epub 2016 Nov 16. Review.

PMID:
27848269
23.

Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers - A pharmacoepidemiological cross-sectional multicenter study.

Dold M, Kautzky A, Bartova L, Rabl U, Souery D, Mendlewicz J, Porcelli S, Serretti A, Zohar J, Montgomery S, Kasper S.

Eur Neuropsychopharmacol. 2016 Dec;26(12):1960-1971. doi: 10.1016/j.euroneuro.2016.10.005. Epub 2016 Nov 2.

PMID:
27816317
24.

Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials.

Dold M, Tardy M, Samara MT, Li C, Kasper S, Leucht S.

World J Biol Psychiatry. 2016 Apr;17(3):210-20. doi: 10.3109/15622975.2015.1083616. Epub 2016 Feb 26.

PMID:
26919194
25.

Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.

Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, Leucht S.

JAMA Psychiatry. 2016 Mar;73(3):199-210. doi: 10.1001/jamapsychiatry.2015.2955.

26.

Lithium for schizophrenia.

Leucht S, Helfer B, Dold M, Kissling W, McGrath JJ.

Cochrane Database Syst Rev. 2015 Oct 28;(10):CD003834. doi: 10.1002/14651858.CD003834.pub3. Review.

27.

Factors contributing to the increasing placebo response in antidepressant trials.

Kasper S, Dold M.

World Psychiatry. 2015 Oct;14(3):304-6. doi: 10.1002/wps.20245. No abstract available.

28.

Increasing placebo response in antipsychotic trials: a clinical perspective.

Dold M, Kasper S.

Evid Based Ment Health. 2015 Aug;18(3):77-9. doi: 10.1136/eb-2015-102098. Epub 2015 Jun 29.

PMID:
26124311
29.

Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials.

Dold M, Fugger G, Aigner M, Lanzenberger R, Kasper S.

Schizophr Res. 2015 Aug;166(1-3):187-93. doi: 10.1016/j.schres.2015.04.024. Epub 2015 May 23.

PMID:
26008883
30.
31.

Second-Generation Antipsychotic Drugs in Anorexia Nervosa: A Meta-Analysis of Randomized Controlled Trials.

Dold M, Aigner M, Klabunde M, Treasure J, Kasper S.

Psychother Psychosom. 2015;84(2):110-116. Epub 2015 Feb 21.

PMID:
25722106
32.

Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.

Dold M, Samara MT, Li C, Tardy M, Leucht S.

Cochrane Database Syst Rev. 2015 Jan 16;1:CD009831. doi: 10.1002/14651858.CD009831.pub2. Review.

PMID:
25592299
33.

Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia.

Tardy M, Dold M, Engel RR, Leucht S.

Cochrane Database Syst Rev. 2014 Sep 1;(9):CD009227. doi: 10.1002/14651858.CD009227.pub2. Review.

PMID:
25177834
34.

Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia.

Tardy M, Dold M, Engel RR, Leucht S.

Cochrane Database Syst Rev. 2014 Jul 8;(7):CD009396. doi: 10.1002/14651858.CD009396.pub2. Review.

PMID:
25003310
35.

Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses.

Huhn M, Tardy M, Spineli LM, Kissling W, Förstl H, Pitschel-Walz G, Leucht C, Samara M, Dold M, Davis JM, Leucht S.

JAMA Psychiatry. 2014 Jun;71(6):706-15. doi: 10.1001/jamapsychiatry.2014.112.

PMID:
24789675
36.

Carbamazepine for schizophrenia.

Leucht S, Helfer B, Dold M, Kissling W, McGrath J.

Cochrane Database Syst Rev. 2014 May 2;(5):CD001258. doi: 10.1002/14651858.CD001258.pub3. Review.

PMID:
24789267
37.

Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective.

Dold M, Leucht S.

Evid Based Ment Health. 2014 May;17(2):33-7. doi: 10.1136/eb-2014-101813. Epub 2014 Apr 8. Review.

PMID:
24713315
38.

Discontinuous patterns of brain activation in the psychotherapy process of obsessive-compulsive disorder: converging results from repeated FMRI and daily self-reports.

Schiepek G, Tominschek I, Heinzel S, Aigner M, Dold M, Unger A, Lenz G, Windischberger C, Moser E, Plöderl M, Lutz J, Meindl T, Zaudig M, Pogarell O, Karch S.

PLoS One. 2013 Aug 15;8(8):e71863. doi: 10.1371/journal.pone.0071863. eCollection 2013.

39.

Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials.

Dold M, Li C, Gillies D, Leucht S.

Eur Neuropsychopharmacol. 2013 Sep;23(9):1023-33. doi: 10.1016/j.euroneuro.2013.03.001. Epub 2013 Apr 17. Review.

PMID:
23602690
40.

Benzodiazepines for schizophrenia.

Dold M, Li C, Tardy M, Khorsand V, Gillies D, Leucht S.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD006391. doi: 10.1002/14651858.CD006391.pub2. Review.

PMID:
23152236
41.

Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.

Dold M, Aigner M, Lanzenberger R, Kasper S.

Int J Neuropsychopharmacol. 2013 Apr;16(3):557-74. doi: 10.1017/S1461145712000740. Epub 2012 Aug 29. Review.

42.

[Effect of the degree of instability during therapy on the treatment outcome of in-patient psychotherapy of obsessive-compulsive disorder].

Dold M, Demal U, Lenz G, Schiepek G, Aigner M.

Neuropsychiatr. 2012;26(1):23-7. doi: 10.1007/s40211-012-0003-0. Epub 2012 May 13. German.

PMID:
22718419
43.

Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses.

Leucht S, Hierl S, Kissling W, Dold M, Davis JM.

Br J Psychiatry. 2012 Feb;200(2):97-106. doi: 10.1192/bjp.bp.111.096594. Review.

PMID:
22297588
44.

[Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomised, placebo-controlled trials].

Dold M, Aigner M, Lanzenberger R, Kasper S.

Fortschr Neurol Psychiatr. 2011 Aug;79(8):453-66. doi: 10.1055/s-0031-1273397. Epub 2011 Aug 1. Review. German.

PMID:
21809258
45.

[Neuroimaging the various symptom dimensions of obsessive-compulsive disorder].

Dold M, Aigner M.

Neuropsychiatr. 2009;23(4):193-205. Review. German.

PMID:
19909691
46.

Delayed allergic response to propofol.

Dold M, Konarzewski WH.

Anaesthesia. 1989 Jun;44(6):533. No abstract available.

Supplemental Content

Support Center